Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 879523, 11 pages
Review Article

Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy

1Department of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan
2Division of Endocrinology and Metabolism, Department of Internal Medicine, Kanazawa Medical University, Ishikawa 920-0293, Japan

Received 30 August 2008; Accepted 8 December 2008

Academic Editor: Nigel Brunskill

Copyright © 2008 Shinji Kume et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Diabetic nephropathy is a leading cause of end-stage renal disease, which is increasing in incidence worldwide, despite intensive treatment approaches such as glycemic and blood pressure control in patients with diabetes mellitus. New therapeutic strategies are needed to prevent the onset of diabetic nephropathy. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear transcription factors that play important roles in lipid and glucose homeostases. These agents might prevent the progression of diabetic nephropathy, since PPAR agonists improve dyslipidemia and insulin resistance. Furthermore, data from murine models suggest that PPAR agonists also have independent renoprotective effects by suppressing inflammation, oxidative stress, lipotoxicity, and activation of the renin-angiotensin system. This review summarizes data from clinical and experimental studies regarding the relationship between PPARs and diabetic nephropathy. The therapeutic potential of PPAR agonists in the treatment of diabetic nephropathy is also discussed.